ARTICLE

Heterogeneous clinical presentation in ICF syndrome: correlation with underlying gene defects

Corry MR Weemaes^{*1}, Maarten JD van Tol², Jun Wang^{3,20}, Monique M van Ostaijen-ten Dam², Marja CJA van Eggermond⁴, Peter E Thijssen³, Caner Aytekin⁵, Nicola Brunetti-Pierri⁶, Mirjam van der Burg⁷, E Graham Davies⁸, Alina Ferster⁹, Dieter Furthner¹⁰, Giorgio Gimelli¹¹, Andy Gennery¹², Barbara Kloeckener-Gruissem^{13,14}, Stephan Meyn¹⁵, Cynthia Powell¹⁶, Ismail Reisli¹⁷, Catharina Schuetz¹⁸, Ansgar Schulz¹⁸, Andrea Shugar¹⁵, Peter J van den Elsen^{4,19} and Silvere M van der Maarel³

Immunodeficiency with centromeric instability and facial anomalies (ICF) syndrome is a primary immunodeficiency, predominantly characterized by agammaglobulinemia or hypogammaglobulinemia, centromere instability and facial anomalies. Mutations in two genes have been discovered to cause ICF syndrome: *DNMT3B* and *ZBTB24*. To characterize the clinical features of this syndrome, as well as genotype–phenotype correlations, we compared clinical and genetic data of 44 ICF patients. Of them, 23 had mutations in *DNMT3B* (ICF1), 13 patients had mutations in *ZBTB24* (ICF2), whereas for 8 patients, the gene defect has not yet been identified (ICFX). While at first sight these patients share the same immunological, morphological and epigenetic hallmarks of the disease, systematic evaluation of all reported informative cases shows that: (1) the humoral immunodeficiency is generally more pronounced in ICF1 patients, (2) B- and T-cell compartments are both involved in ICF1 and ICF2, (3) ICF2 patients have a significantly higher incidence of intellectual disability and (4) congenital malformations can be observed in some ICF1 and ICF2 cases. It is expected that these observations on prevalence and clinical presentation will facilitate mutation-screening strategies and help in diagnostic counseling.

European Journal of Human Genetics (2013) **21**, 1219–1225; doi:10.1038/ejhg.2013.40; published online 13 March 2013

Keywords: ICF syndrome; *DNMT3B*; *ZBTB24*; genotype–phenotype

INTRODUCTION

Immunodeficiency with centromeric instability and facial anomalies (ICF syndrome) (MIM no. 242860) is a rare autosomal recessive disease, characterized by immunodeficiency of variable extent, mild facial anomalies and chromosome instability, involving the pericentromeric regions of chromosomes 1, 9 and 16. Facial dysmorphisms may include a round face, flat nasal bridge, hypertelorism, epicanthus, up-turned nose, macroglossia, micrognathia and low-set ears. The majority of ICF patients have a delay in walking and speech development. The intelligence status is variable.¹

Most patients suffer from hypogammaglobulinemia, or agammaglobulinemia, which is the immunological hallmark of ICF syndrome. Circulating B-cells in ICF patients have been reported to contain an increased proportion of immature cells, a lack of memory cells and are more prone to undergo apoptosis upon *in vitro* activation.

Interestingly, activation, differentiation and immunoglobulin class-switch recombination driven by stimulation via the B-cell receptor and CD40 appeared to be normal.² Studies on T-cell function are limited, and reported data suggest a normal proliferative response upon mitogenic stimulation, the capability to support Pokeweed mitogen (PWM)-induced immunoglobulin production by control B-cells and a somewhat increased degree of apoptosis.^{3,4} Therefore, the relative contribution of an intrinsic B-cell defect and a defective T-cell function to the frequently observed dysgammaglobulinemia in patients with ICF syndrome remains to be elucidated.

Approximately 50% of the ICF cases carry mutations in the DNA methyltransferase 3B gene (*DNMT3B*) at chromosome 20q11.2.^{5,6} These cases have been designated as ICF1 patients.¹ No genotype–phenotype correlation was observed among patients with and without *DNMT3B* mutations in an earlier study.¹ Recently, mutations in the

¹Department of Pediatric Infectious Diseases and Immunology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; ²Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands; ³Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands; ⁴Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands; ⁵Department of Pediatric Immunology, Dr Sami Ulus Maternity and Children's Research and Educational Hospital, Ankara, Turkey; ⁶Department of Pediatrics, Federico II University of Naples, Naples, Italy; ⁷Department of Immunology, Erasmus Medical Center, Rotterdam, The Netherlands; ⁸Centre for Immunodeficiency, Great Ormond Street Hospital and Institute of Child Health, London, UK; ⁹Department of Pediatrics, Haemato-Oncology Unit, Hôpital Universitaire des Enfants Reine Fabiola, Université Libre de Bruxelles, Brussels, Belgium; ¹⁰Landesfrauen und Kinderklinik, Linz, Austria; ¹¹Laboratorio di Citogenetica, Istituto G Gaslini, Genova, Italy; ¹²Department of Paediatric Immunology, Newcastle Upon Tyne Hospital, NHS Foundation Trust, United Kingdom and Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, UK; ¹³Institute of Medical Molecular Genetics, University of Zurich, Zurich, Switzerland; ¹⁴Department of Biology, ETHZ, Zurich, Switzerland; ¹⁵Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, Ontario, Canada; ¹⁶Department of Pediatrics, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ¹⁷Department of Pediatric Immunology and Allergy, Necmettin Erbakan University, Meram Medical Faculty, Konya, Turkey; ¹⁸Department of Pediatrics and Adolescent Medicine, University Hospital Ulm, Ulm, Germany; ¹⁹Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands

*Correspondence: Dr CMR Weemaes, Department of Pediatric Infectious Diseases and Immunology, Radboud University Nijmegen Medical Centre, PO Box 9101, Nijmegen 6500HB, The Netherlands. Tel: +31 24 3614430; Fax: +31 24 3616428; E-mail: c.weemaes@cukz.umcn.nl

²⁰Current address: Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China.

Received 12 December 2012; revised 30 January 2013; accepted 6 February 2013; published online 13 March 2013

zinc-finger and BTB domain-containing 24 gene (*ZBTB24*) on chromosome 6q21 were described in most *DNMT3B* mutation-negative patients, and these cases were designated as ICF2 patients.^{7,8} Mutations in *DNMT3B* or *ZBTB24* do not explain all ICF patients and there remains a small group with unknown etiology,⁷ here provisionally designated as ICFX. In ICF patients, large, often centromeric, DNA repeats show reduced CpG methylation, and ICF2 and ICFX patients differ from ICF1 patients by the presence of additional α -satellite repeat hypomethylation.^{7,9}

The aim of the present study is to identify possible differences in the clinical presentation and immunological characteristics of patients with ICF1, ICF2 and ICFX syndrome.

MATERIALS AND METHODS

Patients

At present, 66 patients have been included in the ICF registry. A computer-assisted literature search using PubMed and EM-base was conducted in order to identify and obtain data on patients with ICF syndrome. Supplementary information was obtained from questionnaires completed by their referring physicians. In 22 patients, molecular analysis was not performed; they were excluded from this study. Data of patients previously reported in the literature were updated ($n=37$) and new patients ($n=7$) have been included. Ethical approval was obtained for the publication of these data.

Data collected included age at diagnosis, facial anomalies, psychomotor development, hypotonia and gastrointestinal problems. The diagnosis of immunodeficiency was primarily based on reductions of serum IgG, IgG subclasses, IgA and/or IgM levels compared to age-matched controls.¹⁰ Agammaglobulinemia was defined as a decrease of IgG level below 2.5 g/l. Special attention was drawn to frequency and type of infections, and laboratory results reflecting the immunological status. Apart from serum immunoglobulin levels, complete blood count, numbers of B-cell and T-cell subpopulations at diagnosis and latest follow-up were included as well. Normal ranges for lymphocyte numbers and subpopulations are from published data.¹¹

Mutation analysis of *DNMT3B* and *ZBTB24*

For all new patients, all coding exons and intron-exon junctions for *DNMT3B* and *ZBTB24* were amplified from gDNA isolated from peripheral blood by PCR and the PCR products were subjected to Sanger sequencing (LGTC, Leiden, the Netherlands) as previously described.⁷ All described variants are based on the reference *DNMT3B* (NM_006892.3) and *ZBTB24* (NM_014797.2) accessions.

In vitro expansion of T-cells

Peripheral blood mononuclear cells (PBMCs) from patients and parents or controls were isolated using a Ficoll-Isopaque gradient. To generate T-cell lines, 5×10^5 or 1×10^6 PBMCs were stimulated by polyclonal activation with 1 μ g/ml phytohaemagglutinin (PHA; Wellcome Diagnostics, Dartford, UK), and irradiated allogeneic PBMCs (3000 rad) in RPMI 1640 (Life Technologies Europe, Bleiswijk, the Netherlands) supplemented with 10% human AB serum, 20 IU/ml recombinant interleukin-2 (rIL-2; Novartis International, Basel, Switzerland), 100 IU/ml streptomycin, 100 IU/ml penicillin and 2 mM L-glutamine. The number of viable T-cells were counted in a Bürker counting chamber at day 7 or 9 following stimulation. An aliquot of 1×10^6 of the responding T-cells was re-stimulated with PHA, rIL-2 and irradiated allogeneic PBMCs. After 7 or 9 days of re-stimulation, the number of responding T-cells was determined again. Cell expansion was defined as the number of cells present at the end of the 7–9-days culture period related to the number of cells at the start of the first or second stimulation, respectively, which was set at 1.

RESULTS

A total of 44 patients were included in the study: 23 with mutations in *DNMT3B* (ICF1), 13 with mutations in *ZBTB24* (ICF2) and 8 without detectable mutations in either gene (ICFX) (Table 1). ICF1 patients 15 and 16, 29 and 33, 35 and 36, 51 and 52, ICF2 patients 37

and 38, 62 and 63 and 64, and ICFX patients 13 and 14, 34 and 53 are siblings. Sociodemographic and genetic data are summarized in Table 1. Dysmorphic features, developmental and neurological complications of the disease, infectious diseases and occurrence of malignancies for the patients in each group are given in Table 2.

Genetics

A new *DNMT3B* (homozygous) mutation c.1918G>C (p.G640R) was identified in patient 50 and we identified an already described homozygous mutation, c.2450A>G (p.D817G), in patient 47. In *ZBTB24*, homozygous mutations c.759C>G (p.T253X) and c.958C>T (p.R320X) were found in patients 40 and 55, respectively, of which the mutation found in patient 40 has not been described before. Most ICF1 patients with mutations in *DNMT3B* carry missense mutations in or near the catalytic domain (Table 1; Figure 1). None are homozygous for nonsense alleles. In contrast, the majority of ICF2 patients have homozygous mutations in *ZBTB24*. There does not seem to be a mutational hotspot in *ZBTB24* and most mutations are predicted to create a premature stop codon (Table 1; Figure 1).

Facial anomalies

Facial anomalies were observed in nearly all patients within the three groups and the pattern of facial anomalies was overlapping between ICF1, ICF2 and ICFX (Table 2). Only patient 25 in group 1 had no facial anomalies, even when he grew older. Hypertelorism, flat nasal bridge and epicanthus were the most common anomalies in all three groups.

Growth and development

Failure to thrive occurred in some patients within all groups. Macronodular cirrhosis developed in ICF1 patient 42 following treatment for acute lymphoblastic leukemia and granulomatous hepatitis in ICF2 patient 54. Motor delay was observed in ~50% of ICF1 patients, but in nearly every ICF2 patient. Speech delay was observed in most patients of all the three groups. In addition, intellectual disability was found in about half of the ICF1 patients (9/20), but in all patients with ICF2 (13/13) ($P=0.001$; χ^2 test). Several patients with ICFX were also intellectually disabled.

Congenital malformations

Congenital malformations were reported in seven patients with ICF1. Cardiac anomalies were reported in three patients (two with a ventricular septal defect and one with atrium septal defect). Cleft lip, clinodactyly and syndactyly, choanal stenosis, hip dislocation and a horseshoe kidney were all mentioned once in a patient. In ICF2, cardiac anomalies were reported as well: once an atrium septal defect and once an ascending aorta dilatation. Congenital hypothyroidism affected ICF1 patient 42.

Cerebral malformations

Cerebral malformations, including corpus callosum hypoplasia and macrocephaly, were reported in several ICF1 patients, and cortical atrophy was mentioned in four patients. Focal cortical heterotopy has been reported in ICF2 patient 40 as well as in ICFX patient 41.¹² ICF2 patient 65 had a large cerebral arachnoidal cyst.¹³ ICF1 patient 42 had a rod/cone retinal dystrophy. It is unclear whether this was coincidental.

Infections

Severe infections (pneumonia, sepsis) occurred in majority of the patients of all three groups. Opportunistic infections (*Candida*

Table 1 Sociodemographic and genetic data of all analyzed ICF patients

ICF1						Follow-up	Age at		
Patient no.	References	Birth year	Sex	Origin	Mutations in DNMT3B transcript NM_006892.3 (protein NP_008823.1)	Cons [†]	status	death (years)	Cause of death
1	1,15	1972	M	English	c.1987G>A; (p.G663S)/c.2177T>G; (p.V726G)	No		14	
2	1,23	1966	M	Italian	c.2441A>G; (p.H814R)/c.2452G>A; (p.V818M)	No		12	Respiratory failure
7	1,24		F	American	c.1807G>A; p.A603T/c.2421-11G>A; p.E806_R807insSTP	NR	Lost		
8	1,25	1985	M	French	1 bp ins codon 53; (p.fsX158)/c.2301 + 139G>A and c.2302-212T>C and c.2421-91G>A; (p.P746_R807del)	No		16	Respiratory failure
15	1,26	1992	M	Dutch	c.2177T>G; p.V726G	Yes		8	Sepsis
16	1	1994	M	Dutch	c.2177T>G; p.V726G	Yes		12	Encephalopathy
24	1,27	1988	F	German	c.1817T>C; (p.V606A)/c.610C>T; (p.Q204X)	No		18	RSV after HSCT for myelodysplastic syndrome
25	1	1982	M	English	c.2296G>C; (p.A766P) (heterozygous)	NR	Lost		
29	1	1996	F	Turkish	c.2421-11G>A; p.E806_R807insSTP	Yes		3	Respiratory infection
30	1,14	1988	M	Dutch/Antillean	c.2096T>G (p.V699G)/c.160C>T (p.R54X)	No		19	Angiosarcoma
31	1,28	1981	M	Japanese	c.88C>T; (p.Q30X)/c.2519G>A; (p.R832Q)	No	Lost		
32	1,29	1995	F	Libanese	c.1754C>T (p.A585V)	Yes	Lost		
33	1,16	2000	M	Turkish	c.2421-11G>A; p.E806_R807insSTP	Yes			
35	1,28	1997	F	Japanese	c.808T>C; (p.S270P)	Yes	Lost		
36	1,28	2001	M	Japanese	c.808T>C; (p.S270P)	Yes	Lost		
42	1	2004	M	Jordanian	c.2476C>T; (p.R826C)	Yes			
43	1,16	2004	F	English	c.2450A>G; (p.D817G)/c.1793T>C; (p.V598A)	No			
45	1	1989	F	Austrian	c.2292G>T; (p.R764S)/c.2342_2343del (p.I781KfsX23)	No			
47		1991	F	Moroccan	c.2450A>G; (p.D817G)	Yes	Lost		
50		1995	F	American	c.1918G>C; (p.G640R)	No	Lost		
51	30		M	Moroccan	c.2450A>G (p.D817G)	Yes		0.75	Peritonitis, sepsis
52	30		F	Moroccan	c.2450A>G (p.D817G)	Yes		2	Sepsis
58	31	2006	F	Saudi	c.2506G>A (p.V836M)	NR		4	Sepsis
ICF2						Follow-up	Age at		
Patient no.	References	Birth year	Sex	Origin	Mutations in ZBTB24 transcript NM_014797.2 (protein NP_055612.2)	Cons [†]	status	death (years)	Cause of death
11	1,7,32	1987	F	Scottish	c.47C>G (p.S16X)	Yes		13	Bronchopneumonia
17	1,7	1983	F	Turkish	c.958C>T (p.R320X)	Yes		11	Pseudomonas sepsis
27	1,4,7	1981	M	Italian	c.1369C>T (p.R457X)	No	Lost		
37	1,7,33	1998	M	German	c.833C>G (p.S278X)/c.1222T>G (p.C408G)	No		4	M Hodgkin
38	1,7,33	2001	F	German	c.833C>G (p.S278X)/c.1222T>G (p.C408G)	No			
40	1,12	2000	M	Turkish	c.759C>G (p.T253X)	Yes			
49	7	2006	M	Turkish	c.917delA (p.N306IfsX4)	Yes			
54	7	1997	M	Turkish	c.501dup (p.V168SfsX28)	Yes			
55		2010	M	Turkish	c.958C>T (p.R320X)	No			
62	8	1997	M	Lebanese	c.396_397del; (p.H132QfsX20)	No			
63	8	1998	M	Lebanese	c.396_397del; (p.H132QfsX20)	No			
64	8	2003	M	Lebanese	c.396_397del; (p.H132QfsX20)	No			
65	13	2003	M	Moroccan	c.1222T>G (p.C408G)	No			
ICFX						Follow-up	Age at		
Patient no.	References	Birth year	Sex	Origin	Mutations	Cons [†]	status	death (years)	Cause of death
13	1,34	1960	F	Italian	Neg	NR		40	Encephalitis
14	1,34	1959	M	Italian	Neg	NR	Lost		
34	1,16	2000	F	English	Neg	No			
41	1,12	1986	M	Turkish	Neg	Yes			
48		2006		Turkish	Neg	Yes			
53		2007		English	Neg	No			
61		2008		Pakistani	Neg	NR			
66		2012		Turkish	Neg	Yes			

Abbreviations: cons[†], consanguinity; F, female; M, male; Neg, negative; NR, not reported.

Numbers refer to the aforementioned patient registry, bold numbers: patient/mutation which has not been described before.

albicans, *Pneumocystis jiroveci*) were found in some patients within all groups (Table 2).

Malignancy

Angiosarcoma has been described in one ICF1 patient¹⁴ and ICF1 patient 42 suffered from an acute lymphoblastic leukemia. Hodgkin lymphoma was described in ICF2 patient 37.¹

Immunodeficiency

Hypogammaglobulinemia or agammaglobulinemia was observed in all but one ICF1 patients (Table 3, Supplementary Figure 1). This boy, patient 2, had normal serum IgG and IgM levels.¹⁵ Agammaglobulinemia occurred in at least 14 patients. All 20 ICF1 patients with known data were IgA deficient. Three had normal IgM levels.

Table 2 Overview of clinical data of the patients

Condition	ICF1	ICF2	ICFX
Number of patients	23	13	8
Deceased	11	3	1
Age range (years)	0.75–19 years	4–13 years	40 years
<i>Facial anomalies</i>			
Hypertelorism	14/18	7/13	6/6
Flat nasal bridge	13/16	8/9	5/5
Epicanthus	14/17	7/8	6/7
Up-turned nose	6/9	4/7	4/6
Macroglossia	5/11	1/5	3/6
Telecanthus	3/11	2/4	3/5
Micrognathia	5/12	3/8	3/6
Low-set ears	6/14	5/7	5/5
Round face	8/10	6/8	4/6
Total incidence	21/22	13/13	7/7
<i>Growth and development</i>			
Gestational age <37 weeks	3/20	1/7	0/5
Birth weight <p10	9/20	4/6	4/5
Failure to thrive	8	3	2
Delay in motor development	9/16	7/8	4/6
Delay in speech development	14/16	11/13	4/6
<i>Malformations</i>			
Congenital	7	2	
Cerebral	2	2	1
<i>Intelligence</i>			
Normal	11/20	0/13	3/7
Retardation	9/20	13/13	4/7
<i>Neurology</i>			
Seizures	3	1	
<i>Gastrointestinal problems</i>			
Diarrhea	7/14	2/6	2/3
<i>Infections</i>			
Otitis	8/13	2/6	1
Bronchopneumonia	16/16	5/7	3
Sepsis	5	1	1
Candida infection	4	2	2
<i>Pneumocystis jirovecii</i>	2	2	2
Malignancy	2	1	

Indicated are the number of patients displaying the respective trait/total number of patients of which data on the respective trait is reported.

In ICF2, one patient had normal serum IgA and IgG levels, concomitant with a normal distribution of IgG subclasses (patient 65, Table 3).¹³ Of twelve ICF2 patients, half had hypogammaglobulinemia, whereas the other half had agammaglobulinemia. IgA was present in (sub)normal levels in seven patients. Likewise in seven patients, IgM was present in a (sub)normal level, whereas four patients had both IgA and IgM at normal concentrations (Table 3).

Six ICFX patients showed agammaglobulinemia (Table 3). One girl (patient 13) with ICFX had only IgM deficiency, but some years later she developed agammaglobulinemia during encephalitis due to JC virus. Her older brother (patient 14) had normal serum immunoglobulins.

In young children, the numbers of CD3⁺, CD4⁺ and CD8⁺ cells were normal both in ICF1 and ICF2 groups (Supplementary Table 1 and Supplementary Figure 2). T-cells become deficient in older children and young adults with ICF1. Four of the ICF1 patients developed a neutropenia and thrombocytopenia (patients 16, 25, 30 and 45) in the second decade; B- and T-cells were decreased as well (Supplementary Figure 2). Bone marrow of patient 16 showed hypoplasia.

Cell expansion after stimulation of PBMC's containing comparable numbers of T-cells with PHA/IL-2 and irradiated allogeneic feeders for 7 or 9 days was significantly reduced in those ICF patients investigated (ICF1: patients 42 and 45, ICF2: patients 49, 54, 55 and 65) compared with unrelated controls, parents or an unaffected sibling ($P=0.028$; Wilcoxon test, Table 4). Significantly reduced expansion was also observed in a second round of stimulation for 7 or 9 days when ICF1 and ICF2 were considered as one group (Table 4).

Treatment

Hematopoietic stem cell transplantation (HSCT) was performed in three unrelated ICF1 patients (patients 24, 33 and 43) and in two siblings (patients 34 and 53) with ICFX. Patient 24 received a HSCT because of myelodysplasia; she died from a RSV infection. In the other patients, HSCT was performed due to severe infections associated with the immunodeficient status and was successful in all cases.¹⁶ Remarkably, HSCT was not performed in ICF2 patients.

DISCUSSION

The hallmarks of ICF syndrome are the triad of immunodeficiency, centromeric instability and facial dysmorphisms. Not surprisingly, these are present in all three groups. Specifically, patients with ICF1 or ICF2 were found to have a similar phenotype. They have the same facial anomalies, a frequent occurrence of developmental delay and a high incidence of severe respiratory and opportunistic infections. These symptoms are also present in ICFX patients with unresolved gene defect. However, despite these common characteristics, subtle differences in immune defects, congenital malformation and intellectual function were observed among the three groups.

Immunodeficiency is severe in ICF syndrome and most patients die at young age, usually in the first or second decade. However, humoral immunodeficiency is generally more pronounced in patients with ICF1 compared with ICF2. In ICF1, all but one patients suffer from agammaglobulinemia or hypogammaglobulinemia, and all are IgA deficient. An ICF1 case with a mild phenotype was recently also reported to have a homozygous c.2308A>G (pK770E) mutation in *DNMT3B*.⁸ In ICF2, immunoglobulin class deficiencies are less extreme: one patient has normal serum immunoglobulins and six of them have normal levels of IgA and/or IgM. Blanco-Betancourt *et al.*² studied two ICF1 patients and two *DNMT3B* mutation-negative ICF patients; three of these patients had agammaglobulinemia. The peripheral blood of these patients contained only naive B-cells, with an immature phenotype, possibly due to an accumulation of new bone marrow B-cell emigrants but no memory B-cells. They proposed that disturbance of peripheral B-cell maturation contributes to agammaglobulinemia in ICF syndrome. *In vitro*, B-cells of the patients were competent in class-switch recombination and immunoglobulin secretion upon stimulation via CD40L in the presence of IL-4. In line with these data, IgA and IgG are present in some ICF2 patients in this study. In one patient (patient 65), the switch is (nearly) normal, based on normal serum IgA and IgG levels (Table 3). Notably, the latter patient is the only ICF2 case

Figure 1 Schematic representation of the DNMT3B and ZBTB24 proteins, and their domains with the mutations identified in ICF1 and ICF2 patients included in this study.

reported to date harboring two missense mutations in *ZBTB24*: all other ICF2 patients have at least one premature stop codon. This indicates the crucial role of *ZBTB24* in antibody production.

With respect to cellular immunity, the number of T-cells is normal in young ICF1 and ICF2 children (below the age of 10 years). However, once older with a long follow-up period, ICF1 patients (patients 16, 25, 30 and 45) display a decline in the numbers of T-cells in the second decade of life, when they develop neutropenia and thrombocytopenia as well (Supplementary Figure 2). Interestingly, it has been suggested that these features, together with development of cerebral atrophy, are reminiscent of systemic lupus erythematosus (SLE),¹ which is linked to DNA hypomethylation.¹⁷ However, mRNA levels of *DNMT3B* in T-cells of SLE patients are comparably low as that in normal controls.¹⁸ In mice, it has been reported that *Dnmt3a* and *Dnmt3b* function as *de novo* methyltransferases during hematopoietic differentiation, and therefore have a critical role in hematopoietic stem cell self-renewal.¹⁹ In line with this notion, mutations in the aforementioned four ICF1 patients are located in the same region (patient 16: p.V726G, patient 25: p.A766P, patient 30: p.V699G and patient 45: p.R764S/p.I781KfsX23), all of which are supposed to reduce the overall stability of DNMT3B protein.²⁰ In contrast, no decline of peripheral counts of neutrophils and thrombocytes has been observed in patients with ICF2 (two of them are >10 years old) or ICFX.

A possible T-cell defect has not been demonstrated in ICF patients as yet. However, opportunistic infections with *Pneumocystis* and *Candida albicans* occurred in several ICF patients irrespective of the group, pointing to a functional T-cell defect. In mice carrying the same missense mutations in *Dnmt3b* identified in ICF1 patients, massive apoptosis of T-cells was observed in the thymus. This T-cell apoptosis appears to occur a few hours after birth, as the thymocyte profiles were normal in embryonic and newborn mice. Flowcytometric analysis of CD4, CD8 and TCR β expression revealed no developmental defect of the T-cells in the thymus of newborn mice.²¹

Likewise, in young ICF patients, the numbers of CD3⁺ T-cells, CD4⁺ and CD8⁺ T-cell subsets are normal, irrespective of the group. However, *in vitro* stimulation of PBMCs with PHA/IL-2 and irradiated allogeneic feeders revealed that the expansion of T-cells was reduced in all ICF1 and ICF2 cases investigated. This decreased expansion was maintained in a second round of stimulation, indicating an intrinsic T-cell defect in ICF1 and ICF2 patients, for instance a disturbed cell cycle progression. Alternatively, the reduction in T-cell numbers after stimulation could also be caused by an increased susceptibility to apoptosis of ICF1 and ICF2 T-cells, which is in line with the results obtained with splenocytes of *Dnmt3b* mutant mice.²¹

All ICF2 patients are intellectually disabled, and nearly all have a delay in development of walking and initial speech. In contrast, only half of the patients with ICF1 are intellectually disabled. Data from the Allen Brain Atlas (www.brain-map.org) shows that *ZBTB24* is highly expressed in the caudate nucleus, an important part of the brain's learning and memory system, and may explain the high incidence of intellectual disability in ICF2. In a study with transgenic mice, it has been suggested that *Dnmt3b* is important for the early phase of neurogenesis.²² Cerebral malformations were demonstrated in some ICF patients, belonging to both ICF1 and ICF2 patient groups.

Congenital malformations are only found in a few patients. Mouse models for ICF syndrome, either *Dnmt3b* knockout mice or mice carrying homozygous *Dnmt3b* mutations identified in ICF1 patients, demonstrated that *Dnmt3b* is essential for embryonic development. *Dnmt3b* deficiency results in embryonic lethality in mice aged E14.5–E16.5, with multiple tissue defects including ventricular septal defect.²¹ In agreement, congenital heart defects were also observed in three patients with *DNMT3B* mutations. Furthermore, two ICF2 patients carrying mutations in *ZBTB24* had a cardiac defect, suggesting the effects of this gene on embryonic development.

In summary, with the identification of *ZBTB24* mutations in *DNMT3B* mutation-negative ICF cases, it is now possible to classify

Table 3 Serum immunoglobulin levels of the different isotypes at first analysis

	Year of birth	Age (years)	IgG (g/l)	IgA (g/l)	IgM (g/l)
<i>ICF1 patient (NR)</i>					
1	1972	1.5	0.17	<0.06	0.07
2	1966	11	16.7	<0.06	3.86
7		0.5	1.19	<0.06	0.11
8	1985	1.5	4.4	<0.06	0.98
15	1992	1	<0.45	<0.06	<0.05
16	1994	0.5	a	<0.06	<0.05
24	1988	6	↓	↓	↓
25	1982	5	0.6	<0.06	1.4
29	1996	1	<0.45	<0.06	0.05
30	1988	3	<0.45	<0.06	0.13
31	1981	16	a	<0.32	<0.20
32		?	↓	↓	↓
33	2000	0.5	a	<0.06	<0.05
35		1	1.55	0.07	0.06
36		<1	1.75	<0.06	0.04
42	2004	<1	a	<0.06	<0.05
43	2004	0.75	0.80	<0.06	0.04
45	1989	16	a	0.10	<0.05
47	1991	0.5	<0.45	0.06	0.06
50	1995	8	a	<0.06	0.12
51	NR	NR	NR	NR	NR
52	NR	NR	NR	NR	NR
58	2006	4	<1.4	<0.23	<0.18
<i>ICF2 patient (NR)</i>					
11	1987	2	1.50	0.07	0.22
17	1983	5	a	<0.06	<0.05
27	1981	13	3.80	0.20	1.24
37	1998	3	<2.0	2.89	0.03
38	2001	0.5	3.0	0.81	0.23
40	2000	1.5	1.70	<0.06	0.10
49	2006	0.5	1.15	<0.06	<0.05
54	1997	0.25	0.38	<0.06	<0.05
55	2010	0.5	1.45	<0.06	<0.05
62	1997	2	3.24	<0.30	0.25
63	1998	6	4.56	2.00	0.41
64	2003	7	1.96	1.56	0.30
65	2003	8	10.1	1.47	0.19
<i>ICFX patient (NR)</i>					
13	1960	29	12.19	1.43	0.15
		35	1.48	0.06	0.18
14	1959	Adult	Normal	Normal	Normal
34	2000	0.75	<0.45	<0.06	<0.05
41	1986		1.50	<0.07	0.15
48	2006	1	2.32	0.01	0.03
53	2007	0.5	a	<0.3	<0.22
61	2008	3	a	<0.2	<0.20
66	2012	0.25	1.11	0.07	0.04

Abbreviations: NR: not reported; Arrow: level is decreased, but actual value is unknown
aImmunoglobulin substitution.

ICF patients into three groups: ICF1 with mutations in *DNMT3*, ICF2 with mutations in *ZBTB24* and ICFX patients with an unknown gene defect. In our study cohort, including two mutations not reported before, ICF1 is the most prevalent (52%), followed by ICF2 (30%). Clinically, the most striking differences are the more pronounced humoral immunodeficiency in ICF1 patients, the absence of

Table 4 Fold increase of T-cell number, relative to counts before treatment, in response to two consecutive rounds of stimulation of PBMCs with PHA/rIL2 for 7–9 days

	First stimulation	Second stimulation
<i>ICF1</i>		
<i>Patient 42</i>	36	14
Mother	43	33
<i>Patient 45</i>	9.3	13.5
Unrelated control	28.5	17.1
<i>ICF2</i>		
<i>Patient 49</i>	9.6	14
Father	19.5	26.7
Mother	15.3	26
Brother	14.1	22
<i>Patient 54</i>	7.4	13.5
Mother	9.5	29
<i>Patient 55</i>	33.6	15.3
Father	48.7	25.5
Mother	51.3	22.8
<i>Patient 65</i>	5.8	3.7
Father	21.1	19.2
Mother	18.8	27.5

congenital malformations in ICFX patients and the significantly higher incidence of intellectual disability in ICF2 patients. These observations on prevalence and clinical presentation may facilitate prioritization of mutation screening, and can be useful in diagnostic counseling as well. Although focus has been on the B-cell compartment, our studies indicate that the immunodeficiency in patients with ICF syndrome is not restricted to a B-cell defect, but also involves the T-cell compartment.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We thank all ICF families for their participation in this study. This study was supported by the National Institute of Allergy and Infectious Diseases (NIAID: AI090135).

- Hagleitner MM, Lankester A, Maraschio P *et al*: Clinical spectrum of immunodeficiency, centromeric instability and facial dysmorphism (ICF syndrome). *J Med Genet* 2008; **45**: 93–99.
- Blanco-Betancourt CE, Moncla A, Milili M *et al*: Defective B-cell-negative selection and terminal differentiation in the ICF syndrome. *Blood* 2004; **103**: 2683–2690.
- Pezzolo A, Prigione I, Facchetti P *et al*: T-cell apoptosis in ICF syndrome. *J Allergy Clin Immunol* 2001; **108**: 310–312.
- Pezzolo A, Prigione I, Chiesa S *et al*: A novel case of immunodeficiency, centromeric instability, and facial anomalies (the ICF syndrome): immunologic and cytogenetic studies. *Haematologica* 2002; **87**: 329–331.
- Hansen RS, Wijmenga C, Luo P *et al*: The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome. *Proc Natl Acad Sci USA* 1999; **96**: 1–6.
- Xu GL, Bestor TH, Bourc'his D *et al*: Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. *Nature* 1999; **402**: 1–5.
- de Greef JC, Wang J, Balog J *et al*: Mutations in ZBTB24 are associated with immunodeficiency, centromeric instability, and facial anomalies syndrome type 2. *Am J Hum Genet* 2011; **88**: 796–804.
- Chouery E, Abou-Ghoch J, Corbani S *et al*: A novel deletion in ZBTB24 in a Lebanese family with immunodeficiency, centromeric instability, and facial anomalies syndrome type 2. *Clin Genet* 2012; **82**: 1–5.

- 9 Jiang YL, Rigolet M, Bourc'his D *et al*: DNMT3B mutations and DNA methylation defect define two types of ICF syndrome. *Hum Mutat* 2005; **25**: 56–63.
- 10 Kanariou M, Petridou E, Liatsis M *et al*: Age patterns of immunoglobulins G, A & M in healthy children and the influence of breast feeding and vaccination status. *Pediatr Allergy Immunol* 1995; **6**: 24–29.
- 11 Comans-Bitter WM, de Groot R, van den Beemd R *et al*: Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. *J Pediatr* 1997; **130**: 388–393.
- 12 Kloeckener-Gruissem B, Betts DR, Zankl A, Berger W, Güngör T: A new and a reclassified ICF patient without mutations in DNMT3B and its interacting proteins SUMO-1 and UBC9. *Am J Med Genet* 2005; **136**: 31–37.
- 13 Cerbone M, Wang J, Van der Maarel SM *et al*: Immunodeficiency, centromeric instability, facial anomalies (ICF) syndrome, due to ZBTB24 mutations, presenting with large cerebral cyst. *Am J Med Genet* 2012; **158A**: 1–4.
- 14 van den Brand M, Flucke UE, Bult P, Weemaes CM, van Deuren M: Angiosarcoma in a patient with immunodeficiency, centromeric region instability, facial anomalies (ICF) syndrome. *Am J Med Genet* 2011; **155A**: 622–625.
- 15 Hultén M: Selective somatic pairing and fragility at 1q12 in a boy with common variable immunodeficiency: a new syndrome. *Clin Genet* 1978; **14**: 294–295.
- 16 Gennery AR, Slatton MA, Bredius RG *et al*: Hematopoietic stem cell transplantation corrects the immunologic abnormalities associated with immunodeficiency-centromeric instability-facial dysmorphism syndrome. *Pediatrics* 2007; **120**: e1341–e1344.
- 17 Sekigawa I, Kawasaki M, Ogasawara H *et al*: DNA methylation: its contribution to systemic lupus erythematosus. *Clin Exp Med* 2006; **6**: 99–106.
- 18 Zhu X, Liang J, Li F *et al*: Analysis of associations between the patterns of global DNA hypomethylation and expression of DNA methyltransferase in patients with systemic lupus erythematosus. *Int J Dermatol* 2011; **50**: 697–704.
- 19 Tadokoro Y, Ema H, Okano M, Li E, Nakauchi H: *De novo* DNA methyltransferase is essential for self-renewal, but not for differentiation, in hematopoietic stem cells. *J Exp Med* 2007; **204**: 715–722.
- 20 Jia D, Jurkowska RZ, Zhang X, Jeltsch A, Cheng X: Structure of Dnmt3a bound to Dnmt3L suggests a model for *de novo* DNA methylation. *Nature* 2007; **449**: 248–251.
- 21 Ueda Y, Okano M, Williams C *et al*: Roles for Dnmt3b in mammalian development: a mouse model for the ICF syndrome. *Development* 2006; **133**: 1183–1192.
- 22 Feng J, Chang H, Li E, Fan G: Dynamic expression of *de novo* DNA methyltransferases Dnmt3a and Dnmt3b in the central nervous system. *J Neurosci Res* 2005; **79**: 734–746.
- 23 Tiepolo L, Maraschio P, Gimelli G *et al*: Multibranched chromosomes 1, 9, and 16 in a patient with combined IgA and IgE deficiency. *Hum Genet* 1979; **51**: 1–11.
- 24 Carpenter NJ, Filipovich A, Blaese RM, Carey TL, Berkel AI: Variable immunodeficiency with abnormal condensation of the heterochromatin of chromosomes 1, 9, and 16. *J Pediatr* 1988; **112**: 1–8.
- 25 Turleau C, Cabanis M, Girault D *et al*: Multibranched chromosomes in the ICF syndrome: immunodeficiency, centromeric instability, and facial anomalies. *Am J Med Genet* 1989; **32**: 1–5.
- 26 Smeets DF, Moog U, Weemaes CM *et al*: ICF syndrome: a new case and review of the literature. *Hum Genet* 1994; **94**: 1–7.
- 27 Schuffenhauer S, Bartsch O, Stumm M *et al*: DNA, FISH and complementation studies in ICF syndrome: DNA hypomethylation of repetitive and single copy loci and evidence for a trans acting factor. *Hum Genet* 1995; **96**: 562–571.
- 28 Shirohzu H, Kubota T, Kumazawa A *et al*: Three novel DNMT3B mutations in Japanese patients with ICF syndrome. *Am J Med Genet* 2002; **112**: 31–37.
- 29 Björck EJ, Bui TH, Wijmenga C, Grandell U, Nordenskjöld M: Early prenatal diagnosis of the ICF syndrome. *Prenat Diagn* 2000; **20**: 828–831.
- 30 Rigolet M, Grégoire A, Lefort G *et al*: Early prenatal diagnosis of ICF syndrome by mutation detection. *Prenat Diagn* 2007; **27**: 1075–1078.
- 31 Kaya N, Al-Muhsen S, Al-Saud B *et al*: ICF syndrome in Saudi Arabia: immunological, cytogenetic and molecular analysis. *J Clin Immunol* 2011; **31**: 245–252.
- 32 Brown DC, Grace E, Sumner AT, Edmunds AT, Ellis PM: ICF syndrome immunodeficiency, centromeric instability and facial anomalies: investigation of heterochromatin abnormalities and review of clinical outcome. *Hum Genet* 1995; **96**: 1–6.
- 33 Schuetz C, Barbi G, Barth TF *et al*: ICF syndrome: high variability of the chromosomal phenotype and association with classical Hodgkin lymphoma. *Am J Med Genet* 2007; **143A**: 2052–2057.
- 34 Gimelli G, Varone P, Pezzolo A, Lerone M, Pistoia V: ICF syndrome with variable expression in sibs. *J Med Genet* 1993; **30**: 1–5.

Supplementary Information accompanies this paper on European Journal of Human Genetics website (<http://www.nature.com/ejhg>)